BioAtla (BCAB) to Release Earnings on Thursday

BioAtla (NASDAQ:BCAB) is projected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, April 1, 2026 at 4:00 PM ET.

BioAtla Price Performance

NASDAQ:BCAB opened at $0.15 on Wednesday. BioAtla has a fifty-two week low of $0.13 and a fifty-two week high of $1.43. The stock has a market capitalization of $9.40 million, a PE ratio of -0.13 and a beta of 1.08. The business’s 50-day simple moving average is $0.22 and its 200-day simple moving average is $0.55.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Rodman & Renshaw assumed coverage on shares of BioAtla in a report on Tuesday, January 13th. They set a “buy” rating and a $4.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioAtla presently has an average rating of “Hold” and an average target price of $4.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BCAB. ADAR1 Capital Management LLC acquired a new position in BioAtla during the fourth quarter worth $104,000. Jane Street Group LLC lifted its stake in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after acquiring an additional 123,597 shares during the last quarter. Millennium Management LLC acquired a new stake in BioAtla in the third quarter valued at $235,000. Vanguard Group Inc. grew its position in shares of BioAtla by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after acquiring an additional 162,647 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of BioAtla by 968.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after acquiring an additional 1,531,994 shares during the period. 77.23% of the stock is currently owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.